Medtech Industry Reaches New Chapter In Its Structural Evolution

Big Ticket M&A Sporadically Eye-Catching In 2023-24

04 Dec 2024

The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.

Pixelated word 'Top 100' made from cubes, mosaic pattern — The top 100 medtech companies recorded more growth but portfolios targeted at the pandemic saw less demand

A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by revenues.

Nevertheless, certain companies were ready to pay out multi-billions for the right targets.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Outlook 2025: Will Geopolitics Dampen Pharma’s Comeback Party?

09 Dec 2024

• By Jo Shorthouse

The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.

Biopharma Plumps Pipeline With Healthy Weight Loss Candidates

09 Dec 2024

• By Melanie Senior

Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.

Benzos to Breakthroughs: Bill Burns on Roche's Transformation

05 Dec 2024

• By Jo Shorthouse

Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.